How big is Apellis Pharmaceuticals, Inc.?

As of Jun 18, Apellis Pharmaceuticals, Inc. has a market capitalization of $2.23 billion, with net sales of $775.85 million and a net profit of -$223.68 million over the latest four quarters.

Market Cap: As of Jun 18, Apellis Pharmaceuticals, Inc. has a market capitalization of 2,232.12 million, classifying it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Apellis Pharmaceuticals, Inc. reported net sales of 775.85 million and a net profit of -223.68 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 228.54 million and total assets of 885.05 million.

What does Apellis Pharmaceuticals, Inc. do?

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. As of March 2025, it has a market cap of approximately $2.23 billion, with net sales of $167 million and a net loss of $92 million.

Overview: <BR>Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 167 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -92 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2,232.12 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.61 <BR>Return on Equity: -135.02% <BR>Price to Book: 13.59<BR><BR>Contact Details: <BR>Address: 100 5th Avenue, WALTHAM MA : 02451 <BR>Tel: ['1 617 9775700', '1 212 6001902'] <BR>Fax: 1 302 6555049 <BR>Website: http://apellis.com/

Should I buy, sell or hold Apellis Pharmaceuticals, Inc.?

Who are in the management team of Apellis Pharmaceuticals, Inc.?

As of March 2022, the management team of Apellis Pharmaceuticals, Inc. includes Dr. Cedric Francois as CEO and several independent directors, including Dr. Gerald Chan (Chairman), Mr. A. Sinclair Dunlop, Mr. Paul Fonteyne, Mr. Alec Machiels, and Ms. Stephanie O'Brien.

As of March 2022, the management team of Apellis Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Gerald Chan, who serves as the Independent Chairman of the Board.<BR>- Dr. Cedric Francois, who is the President, Chief Executive Officer, Co-Founder, and Director.<BR>- Mr. A. Sinclair Dunlop, who is an Independent Director.<BR>- Mr. Paul Fonteyne, who is an Independent Director.<BR>- Mr. Alec Machiels, who is an Independent Director.<BR>- Ms. Stephanie O'Brien, who is an Independent Director.<BR><BR>In summary, the management team consists of a mix of executive leadership and independent directors, with Dr. Cedric Francois leading as the CEO.

Is Apellis Pharmaceuticals, Inc. overvalued or undervalued?

As of February 25, 2021, Apellis Pharmaceuticals is considered risky and overvalued due to high valuation ratios and poor performance, including a YTD return of -26.73% and an ROE of -135.02%.

As of 25 February 2021, the valuation grade for Apellis Pharmaceuticals, Inc. has moved from does not qualify to risky, indicating increased caution for investors. The company appears to be overvalued, given its negative valuation ratios, including a Price to Book Value of 14.76 and an EV to Sales ratio of 3.25, which are significantly higher than many of its peers. Notably, Exelixis, Inc. has a P/E ratio of 15.81 and an EV to EBITDA of 11.97, showcasing a more favorable valuation profile.<BR><BR>The company's recent performance has been concerning, with a YTD return of -26.73% compared to the S&P 500's 12.22%, highlighting a stark underperformance. Additionally, the ROE stands at -135.02%, further emphasizing the challenges Apellis faces in generating returns for shareholders. Overall, the combination of high valuation ratios and poor stock performance suggests that Apellis Pharmaceuticals is overvalued in the current market context.

Is Apellis Pharmaceuticals, Inc. technically bullish or bearish?

As of October 31, 2025, Apellis Pharmaceuticals has shifted to a neutral technical stance with mixed signals, showing a year-to-date return of -35.85%, significantly underperforming the S&P 500's 16.30%.

As of 31 October 2025, the technical trend for Apellis Pharmaceuticals, Inc. has changed from bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. The weekly RSI shows no signal, but the monthly RSI is bearish. Bollinger Bands indicate bearish conditions for both weekly and monthly periods. Daily moving averages are mildly bullish, but the KST and Dow Theory show no trend on both weekly and monthly time frames. <BR><BR>In terms of performance, the stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -35.85% compared to the S&P 500's 16.30%, and a one-year return of -26.84% against 19.89% for the benchmark.